Mesa Labs Q4 net loss of $254.6M on $274.5M impairment; core organic revenues down 3.5%

MESA LABORATORIES INC /CO/

Q4 revenue $58.9M (+6% YoY); core organic revenue declined 3.5% due to headwinds in Clinical Genomics and Biopharma.
Full-year operating loss of $272.1M includes $274.5M non-cash impairment of goodwill and long-lived assets.
Non-GAAP AOI excluding unusual items rose 26.3% in Q4 to $14.9M; full-year AOI +0.7% to $50.5M.
Clinical Genomics division restructured with 17 position eliminations, expects ~$3M annual savings.
SDC division grew 37.3% (including GKE China acquisition); BPD and CG declined organically.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.